This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Cyclosporin A

Authoring team

This is an immunosuppressive drug that is becoming the drug of choice for transplantation. It may be of use in the management of severe autoimmune diseases.

Cyclosporin blocks cytotoxic T cell activation by:

  • inhibits the formation of a calcineurin-dependent factor essential for the transcription of the interleukin-2 gene, thereby reducing production of interleukin (IL2) by activated T cells and inhibits expression of IL-2 receptors by cytotoxic T cells
  • reduces the response of T helper cells to IL-1
  • does not affect proliferation of suppressor T cells
  • inhibits interferon production by lymphocytes

The bioavailability of cyclosporin A is dependent on the presence of bile salts which may be reduced in patients with liver transplantation. This problem however has been significantly reduced since the advent of a micro-emulsion formulation of cyclosporin whose absorption is independent of bile in the small intestine.

Patients treated with cyclosporin A should have their blood pressure and renal function monitored regularly.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.